PBYI - Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement

Puma Biotechnology (PBYI) and  French pharmaceutical company Pierre Fabre have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX (neratinib) within Europe, Turkey, Middle East and Africa. Under the terms of the amendment, Puma will receive an upfront payment of $50M, as well as additional regulatory and sales-based milestone payments that could add up to an additional $240M.The amended agreement extends Pierre Fabre’s commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.Puma will also receive significant double-digit tiered royalties on the sales of NERLYNX in Greater China.

For further details see:

Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement